Physician profile
Anna Bite
NPI 1659786622
$296,195.16
in general payments reported to CMS, 2019-2025
23 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $8,647 · 2021: $8,066 · 2022: $16K · 2023: $36K · 2024: $47K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Travel and Lodging: $11K · Food and Beverage: $8,776 · Consulting Fee: $4,225 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,432.75 |
| Travel and Lodging | $10,979.92 |
| Food and Beverage | $8,776.09 |
| Consulting Fee | $4,225.00 |
| Education | $166.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $145,815.65 | 2020-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $86,361.34 | 2019-2023 | Tysabri, Vumerity |
| Tg Therapeutics, INC. | $24,943.98 | 2023-2025 | |
| Medtronic USA, INC. | $20,000.00 | 2019 | |
| Genentech USA, INC. | $13,332.64 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Abbvie INC. | $1,925.35 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Genentech, INC. | $1,219.49 | 2021-2025 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $1,136.59 | 2019-2023 | Kesimpta |
| Genzyme Corporation | $503.60 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $414.05 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $144.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $109.01 | 2023-2024 | Austedo Xr |
| Celgene Corporation | $53.37 | 2022-2023 | Zeposia |
| Csl Behring | $48.11 | 2020-2024 | Hizentra |
| Pfizer INC. | $41.06 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $30.38 | 2021-2022 | |
| Argenx US, INC. | $23.16 | 2024 | Vyvgart |
| Amgen INC. | $18.38 | 2020 | |
| Banner Life Sciences, LLC | $17.29 | 2023 | |
| Kyowa Kirin, INC. | $15.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.67 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.40 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.